Past performance does not predict future results. Informational only, not investment advice.
Novel tumor treatment breakthrough in FDA trials with major pharma partners. Company raised sufficient capital through 2027 and trades 50% below recent capital raise price, offering potential 10-20x return within 18 months.
INTS' non-covalent injectable delivery platform for oncology drugs represents a revolutionary breakthrough with no current competition. Phase 3 readout and FDA approval could unlock a 1-5B market cap (20-100x upside from $0.80) by enabling treatment of previously toxic drugs and expanding use beyond the current INT230-6 candidate.
INTS published peer-reviewed clinical data showing their tumor-injected therapeutic extended median survival from 3 to 18 months in heavily pretreated advanced cancer patients with 83% disease control rate. The company has achieved a major breakthrough after 13 years of R&D, positioning it for acquisition by major pharma.
End of results.